Recent Updates
Recently added Catalysts

Cryo-Touch III

Phase 2

Facial Wrinkles | Unknown | Dermatology |Pacira BioSciences, Inc.|Last Updated: Mar 24, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment88
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01379365Cryo-Touch III Refinement Study Investigational PlanPHASE2 COMPLETED 88Jun 1, 2011Dec 1, 2014Mar 24, 20151 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Wrinkle Severity and incidence of device-related serious adverse events
Up to 4 months

* Effectiveness endpoint: Wrinkle severity in the target area in animation at 30 days post-treatment as rated by the investigator using the 5-point grading scale. * Safety endpoint: Incidence of device-related serious adverse events (DSAE).

Secondary Endpoints
Wrinkle Severity
Up to 4 months
Independent Assessment
Up to 4 months
Global assessment
Up to 4 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TreatmentEXPERIMENTAL -
Interventions
NameTypeDescription
Cryo-Touch IIIDEVICEPercutaneous treatment with the device
Unlock Study Design Details
Eligibility Criteria
Age Range30 Years — 70 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Age 30-70 years * Subject has a glabellar and/or forehead wrinkle rating by investigator of at least 2 in animation on the 5-point Wrinkle Scale (5WS)\* * Subject has signed institutional review board (IRB)-approved informed consent form Exclusion Criteria: * Subject takes a...

Countries:United States
Unlock Eligibility Criteria